Study guide
19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety
Key Takeaways Explain This Topic AI
Reliability is the consistency of a measure (test-retest, interrater, internal consistency with Cronbach's alpha of 0.70 or higher); validity is whether it measures what it claims to, and a measure can be reliable without being valid.
A p-value below 0.05 means results this extreme would be unlikely if the null hypothesis were true; statistical significance does not guarantee clinical significance.
A type I error is a false positive (rejecting a true null hypothesis, alpha); a type II error is a false negative (beta), and power (1 minus beta, usually 0.80) depends heavily on sample size.
Sensitivity and specificity are fixed properties of a test, while positive and negative predictive values change with disease prevalence; NNT is 1 divided by the absolute risk reduction.
SBAR, TeamSTEPPS 'CUS' words, closed-loop communication, and root cause analysis within a Just Culture are core interprofessional safety tools.
Last updated: October 2026
The Evidence-Based Practice Process
Evidence-based practice (EBP) combines the best research evidence , clinical expertise , and patient values and preferences .
Ask a focused question in PICOT format: Population, Intervention, Comparison, Outcome, Time. Example: In postpartum women with preeclampsia (P), does home blood pressure monitoring (I), compared with office visits (C), increase completed blood pressure checks (O) within 10 days of discharge (T)?
Acquire the evidence (databases, guidelines).
Appraise it for validity, results, and applicability.
Apply it, integrating patient preferences.
Assess outcomes and disseminate the findings.
- Hierarchy of Evidence (Strongest to Weakest for Intervention Questions)
- Systematic reviews and meta-analyses of randomized controlled trials (RCTs)
- Well-designed RCTs
- Controlled trials without randomization
- Cohort and case-control studies
- Systematic reviews of descriptive or qualitative studies
- Single descriptive or qualitative studies
- Expert opinion and committee reports
USPSTF grades: A (high certainty of substantial benefit), B (moderate to substantial benefit), C (small benefit, so individualize), D (no benefit or harm outweighs benefit, so recommend against), and I (insufficient evidence).
Study Designs
Design Description Measure Strengths and Limits
Randomized controlled trial Participants randomly assigned to intervention or control, ideally blinded Relative risk, absolute risk reduction Best for causation; intention-to-treat analysis keeps randomization intact
Cohort (prospective or retrospective) Groups defined by exposure, followed for outcomes Relative risk , incidence Good for common outcomes and multiple outcomes; prone to confounding
Case-control Groups defined by outcome, looking back at exposures Odds ratio Efficient for rare diseases ; recall bias
Cross-sectional One point in time Prevalence Cannot establish temporal sequence
Qualitative (phenomenology, grounded theory, ethnography) Explores lived experience and meaning Themes Rich understanding; not generalizable by design
- Research Terminology on the Blueprint
- Reliability (Consistency)
Test-retest: Similar results when repeated over time.
Interrater: Agreement between observers (Cohen's kappa).
Internal consistency: Items on a scale measure the same concept ( Cronbach's alpha of 0.70 or higher is acceptable).
Validity (Accuracy)
Measurement validity: Content validity (covers the domain), construct validity (measures the theoretical concept), and criterion validity (agrees with a gold standard, either concurrent or predictive).
Internal validity: Confidence that the intervention, not bias or confounding, caused the outcome. Threats include selection bias, confounding, attrition, history, maturation, and testing effects.
External validity: Generalizability to other populations and settings.
A measure can be reliable but not valid (consistently wrong), but it cannot be valid without being reliable.
Significance
Statistical significance: A p-value below 0.05 means that, if there were truly no effect, results at least this extreme would occur less than 5% of the time. A 95% confidence interval that excludes 1 (for a ratio) or 0 (for a difference) is significant.
Clinical significance: Whether the effect is large enough to matter to patients. A large study can make a trivial difference statistically significant.
Type I error (alpha): Concluding there is an effect when there is none (false positive).
Type II error (beta): Missing a real effect (false negative). Power = 1 − beta , typically set at 0.80 , and rises with sample size and effect size.
Variables and Measurement Levels
Independent variable (the intervention or exposure), dependent variable (the outcome), and confounders (related to both).
Levels: nominal (categories, such as blood type), ordinal (ranked, such as pain mild/moderate/severe), interval (equal intervals, no true zero, such as temperature in °F), and ratio (true zero, such as weight).
Screening and Treatment Effect Math
Term Formula Memory Aid
Sensitivity True positives ÷ (true positives + false negatives) SnNout : a negative result on a highly sensitive test rules out disease
Specificity True negatives ÷ (true negatives + false positives) SpPin : a positive result on a highly specific test rules in disease
- Positive predictive value True positives ÷ all positives Rises with prevalence
- Negative predictive value True negatives ÷ all negatives Falls as prevalence rises
- Absolute risk reduction (ARR) Control event rate − treatment event rate
- Relative risk reduction ARR ÷ control event rate
- Number needed to treat (NNT) 1 ÷ ARR
Worked example: If preeclampsia occurs in 10% of controls and 6% of treated patients, ARR = 4%, relative risk reduction = 40%, and NNT = 1 ÷ 0.04 = 25 . This is also why cfDNA has a lower positive predictive value in a young patient: the test's sensitivity and specificity are unchanged, but the condition is less prevalent.
Research Ethics and Utilization
Belmont Report principles: Respect for persons (informed consent), beneficence, and justice.
Institutional review boards protect participants; federal rules give additional protections to pregnant people, fetuses, prisoners, and children.
Research utilization and implementation: Models such as the Iowa Model and Stetler Model guide translating evidence into practice, with pilot testing, staff education, and outcome evaluation.
Quality Improvement
Donabedian framework: Structure (resources, staffing), process (what is done, such as the percentage of postpartum hypertensive patients with a blood pressure check within 10 days), and outcome (results, such as postpartum stroke rates), plus balancing measures that capture unintended effects.
Model for Improvement: What are we trying to accomplish? How will we know a change is an improvement? What change can we make? Test changes with Plan-Do-Study-Act (PDSA) cycles, starting small and tracking data on run charts .
QI vs. research: QI applies known evidence locally to improve care; research generates generalizable knowledge and requires IRB oversight. Projects that plan to publish generalizable findings may need IRB review.
Patient Safety
Swiss cheese model: Harm occurs when holes in multiple defenses line up, so fix systems rather than blaming individuals.
Just Culture: Console human error, coach at-risk behavior, and hold reckless behavior accountable.
Root cause analysis: Required by The Joint Commission after sentinel events (for example, maternal death or severe maternal morbidity, wrong-site surgery, or a retained foreign object); it seeks system causes and an action plan.
National Patient Safety Goals: Use two patient identifiers, reconcile medications, report critical results promptly, practice hand hygiene, and handle high-alert medications (insulin, magnesium sulfate, oxytocin, anticoagulants, opioids) with double checks.
Disclosure: Communicate openly with patients after an adverse event, with an apology and an explanation of corrective steps (communication-and-resolution programs such as CANDOR).
Communication and Interprofessional Practice
SBAR: S ituation, B ackground, A ssessment, R ecommendation for concise handoffs and escalation.
TeamSTEPPS tools: CUS ("I am C oncerned, I am U ncomfortable, this is a S afety issue"), the two-challenge rule , call-outs, check-back (closed-loop communication) , and structured handoffs (I-PASS).
Chain of command: Escalate unresolved safety concerns up the clinical hierarchy.
Simulation drills for obstetric hemorrhage, shoulder dystocia, and eclampsia improve team performance.
Interprofessional Education Collaborative competencies: Values and ethics, roles and responsibilities, interprofessional communication, and teams and teamwork.